Provided by Tiger Trade Technology Pte. Ltd.

Kyverna Therapeutics

6.41
+0.22503.64%
Volume:667.47K
Turnover:4.28M
Market Cap:396.11M
PE:-2.22
High:6.58
Open:6.20
Low:6.18
Close:6.18
52wk High:13.67
52wk Low:5.96
Shares:61.84M
Float Shares:39.72M
Volume Ratio:0.74
T/O Rate:1.68%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.8809
EPS(LYR):-3.6445
ROE:-87.24%
ROA:-44.51%
PB:2.39
PE(LYR):-1.76

Loading ...

Kyverna Therapeutics Reports Positive 1-Year KYSA-8 Trial Data for Miv-Cel in Stiff Person Syndrome

Reuters
·
Oct 07

Health Rounds: Appendix Removal Linked with Lower Colon Cancer Risk in Study

Reuters
·
Oct 02

US Stocks on the MOVE-Charles River, Oracle, TD Synnex

Reuters
·
Sep 24

Analysts Offer Insights on Healthcare Companies: Aethlon Medical (AEMD) and Kyverna Therapeutics, Inc. (KYTX)

TIPRANKS
·
Sep 24

U.S. Stocks on the MOVE-Everpure, Dropbox, Darden Restaurants

Reuters
·
Sep 24

Kyverna Rises as Cell Therapy Shows Durable Benefit in Rare Nerve Disease

Reuters
·
Sep 24

Swarmer’s miv-cel shows positive results in stiff person syndrome and gMG

TIPRANKS
·
Sep 24

Kyverna Reports Positive 1-Year KYSA-8 Trial Data for Miv-Cel in Stiff Person Syndrome

Reuters
·
Sep 24

Kyverna Therapeutics Reports Positive One-Year Data Demonstrating Durable Clinical Responses and Favorable Safety Profile for Miv-Cel in Stiff Person Syndrome and Generalized Myasthenia Gravis

THOMSON REUTERS
·
Sep 24

Kyverna Therapeutics, - Phase 3 Kysa-6 Trial Enrollment Expected to be Completed in Mid-2027

THOMSON REUTERS
·
Sep 24

Kyverna Therapeutics, - Miv-Cel Well-Tolerated in Gmg Trial with no High-Grade Crs, Icans, or Iec-Hs

THOMSON REUTERS
·
Sep 24

Kyverna Therapeutics to Present at Wells Fargo Healthcare Conference Fireside Chat

Reuters
·
Sep 03

Kyverna Therapeutics: Buy Rating Reiterated as Pipeline Progress and Strong Financial Runway Support Unchanged $25 Price Target

TIPRANKS
·
Aug 12

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Tecan Group AG (OtherTCHBF), Kyverna Therapeutics, Inc. (KYTX) and Pliant Therapeutics (PLRX)

TIPRANKS
·
Aug 12

Kyverna Therapeutics, Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 12

Kyverna Therapeutics Q2 EPS $(0.63) Beats $(0.68) Estimate

Benzinga Earnings
·
Aug 12

Kyverna Therapeutics reports Q2 EPS (63c), consensus (68c)

TIPRANKS
·
Aug 12

Kyverna Therapeutics Rilis Presentasi Investor Soal Terapi CAR-T Miv-Cel Untuk Penyakit Autoimun Neurologis

Reuters
·
Aug 12

Kyverna Therapeutics Rugi Bersih Q2 FY26 Menyempit Jadi USD 38,32 Juta

Reuters
·
Aug 12

Kyverna Therapeutics - on Track to Complete Rolling Bla Submission for Miv-Cel in SPS in Q4 2026

THOMSON REUTERS
·
Aug 12